Sino Biopharmaceutical has announced on the Hong Kong Stock Exchange that the first-class innovative drug, Envolacib (TQ-B3139) (trade name: Anloqin) independently researched and developed by the group, has obtained the marketing approval of the National Medical Products Administration of China and is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who are ALK-positive and have not been treated with ALK inhibitors.
中国生物制药：1类创新药枸橼酸依奉阿克胶囊"Envonalkib (TQ-B3139)"获批上市
Sino Biopharm's Class 1 innovative drug, Envonalkib (TQ-B3139) Citrate Ibrutinib Capsules, has been approved for listing.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.